These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 20307245)

  • 1. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
    Ohrling K; Edler D; Hallström M; Ragnhammar P
    Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
    Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
    J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
    Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
    Bendardaf R; Lamlum H; Ristamäki R; Korkeila E; Syrjänen K; Pyrhönen S
    Acta Oncol; 2008; 47(6):1046-53. PubMed ID: 17943475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
    Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
    Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients.
    Lanza G; Gafà R; Santini A; Maestri I; Guerzoni L; Cavazzini L
    J Clin Oncol; 2006 May; 24(15):2359-67. PubMed ID: 16710035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
    Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
    J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
    Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
    [No Abstract]   [Full Text] [Related]  

  • 10. Absence of hMLH1 or hMSH2 expression as a stage-dependent prognostic factor in sporadic colorectal cancers.
    Park JW; Chang HJ; Park S; Kim BC; Kim DY; Baek JY; Kim SY; Oh JH; Choi HS; Park SC; Jeong SY
    Ann Surg Oncol; 2010 Nov; 17(11):2839-46. PubMed ID: 20549564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunophenotypic evaluation of DNA mismatch repair markers in 2 cases of synchronous histomorphologically distinct gastric adenocarcinomas with gastrointestinal stromal tumors of the proximal small bowel.
    Athanassiou E; Vamvakopoulou DN; Zacharoulis D; Paroutoglou G; Sioutopoulou D; Tepetes K; Nomikos I; Vamvakopoulos NC
    Appl Immunohistochem Mol Morphol; 2010 May; 18(3):288-90. PubMed ID: 20090515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An alternative pathway in colorectal carcinogenesis based on the mismatch repair system and p53 expression in Korean patients with sporadic colorectal cancer.
    Kim HR; Kim HC; Yun HR; Kim SH; Park CK; Cho YB; Yun SH; Lee WY; Chun HK
    Ann Surg Oncol; 2013 Nov; 20(12):4031-40. PubMed ID: 22732839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microsatellite instability testing and its role in the management of colorectal cancer.
    Kawakami H; Zaanan A; Sinicrope FA
    Curr Treat Options Oncol; 2015 Jul; 16(7):30. PubMed ID: 26031544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of DNA Mismatch Repair Protein Abnormalities in Sudanese Colorectal Cancer Patients Using Immunohistochemical Methods.
    Zakout YM; Lanza G
    J Gastrointest Cancer; 2019 Sep; 50(3):530-536. PubMed ID: 29850986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers.
    Kato M; Takano M; Miyamoto M; Sasaki N; Goto T; Tsuda H; Furuya K
    J Gynecol Oncol; 2015 Jan; 26(1):40-5. PubMed ID: 25310854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.
    Ide T; Kitajima Y; Ohtaka K; Mitsuno M; Nakafusa Y; Miyazaki K
    Oncol Rep; 2008 Jun; 19(6):1571-6. PubMed ID: 18497967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas.
    de Jong RA; Boerma A; Boezen HM; Mourits MJ; Hollema H; Nijman HW
    Int J Cancer; 2012 Oct; 131(8):1828-36. PubMed ID: 22287095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer.
    Bendardaf R; Lamlum H; Ristamäki R; Korkeila E; Syrjänen K; Pyrhönen S
    Tumour Biol; 2007; 28(4):212-20. PubMed ID: 17717427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
    Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.